Cárdaba-García, María EAbad-Lecha, EncarnaciónCalleja-Hernández, Miguel Á2023-02-092023-02-092021http://hdl.handle.net/10668/18260Background/Aims. Despite the high efficacy and safety of direct-acting antivirals against hepatitis C virus shown in clinical trials, treatment failures continue to occur. Our aim was to establish the effectiveness of these drugs in routine clinical practice, as well as to determine factors that could influence the response to the treatment.Matherials/methods. Single-center, observational, retrospective study. Clinical, virological and pharmacotherapeutic variables were registered at baseline. Adverse drug reactions that occurred were recorded until week 24 of follow-up. Achievement of sustained virologic response was also recorded. Univariate and multivariate analysis were done to determine factors of response.Results. A total of 333 treatment regimens corresponding to 330 different patients were evaluated. Sustained virologic response rate was 94.6% [95%CI: 91.6-96.6%]. 67.9% of the patients experienced adverse drugs reactions (92.2% were grade 1). The univariate analysis identified a higher baseline of platelets, albumin and total cholesterol as predictive factors of sustained virologic response (p enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/antiviral agentschronic hepatitis Chepatitis C viruspredictive factors of responsesustained virologic responseAntiviral AgentsDrug Therapy, CombinationHepacivirusHepatitis C, ChronicHumansPharmaceutical PreparationsRetrospective StudiesTreatment Outcomeresearch article34308801open access10.1080/19932820.2021.19497971819-6357PMC8317931https://www.tandfonline.com/doi/pdf/10.1080/19932820.2021.1949797?needAccess=truehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317931/pdf